Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | AKT1 | P31749 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 7/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | FAAH | O00519 | 2/20 | 0.47 |
| ▸ | MGLL | Q99685 | 2/20 | 0.47 |
| ▸ | CA12 | O43570 | 4/20 | 0.46 |
| ▸ | CA1 | P00915 | 4/20 | 0.46 |
| ▸ | CA2 | P00918 | 4/20 | 0.46 |
| ▸ | CA9 | Q16790 | 4/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7801592 | 0.99 | TDP1 (0.56) | TDP1AKT1DRD2MAOAMAOB | |
| SCHEMBL17738032 | 0.99 | TDP1 (0.56) | TDP1AKT1DRD2MAOAMAOB | |
| SCHEMBL28508194 | 0.99 | TDP1 (0.56) | TDP1AKT1DRD2MAOAMAOB | |
| SCHEMBL3154615 | 0.95 | TDP1 (0.51) | TDP1AKT1DRD2MAOAMAOB | |
| SCHEMBL998261 | 0.89 | AKT1 (0.59) | TDP1AKT1DRD2MAOAMAOB | |
| SCHEMBL30269019 | 0.87 | PTGS1 (0.48) | TDP1AKT1DRD2FAAHMGLL | |
| SCHEMBL25934863 | 0.86 | PTGS1 (0.46) | TDP1AKT1DRD2FAAHMGLL | |
| SCHEMBL15607620 | 0.86 | AKT1 (0.47) | TDP1AKT1DRD2MAOAMAOB | |
| SCHEMBL2579857 | 0.86 | AKT1 (0.57) | TDP1AKT1DRD2MEN1GAA | |
| SCHEMBL22100919 | 0.85 | CA1 (0.51) | TDP1AKT1DRD2MEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260021192-A1 | PROTEINS HAVING A COVALENT WARHEAD | TOPAZ THERAPEUTICS INC (US) | 2026-01-22 | — | — | US | disclosed |
| EP-4626489-A1 | PCTA DERIVATIVES, CONJUGATES THEREOF AND USES THEREOF | Novartis AG (CH) | 2025-10-08 | — | — | EP | disclosed |
| WO-2024116053-A1 | PCTA DERIVATIVES, CONJUGATES THEREOF AND USES THEREOF | NOVARTIS AG (CH) | 2024-06-06 | — | — | WO | disclosed |
| US-11345715-B2 | Biologically active molecules, conjugates thereof, and therapeutic uses | REGENERON PHARMACEUTICALS, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| US-20200277306-A1 | BIOLOGICALLY ACTIVE MOLECULES, CONJUGATES THEREOF, AND THERAPEUTIC USES | REGENERON PHARMACEUTICALS, INC. | 2020-09-03 | — | — | US | disclosed |
| US-10570151-B2 | Biologically active molecules, conjugates thereof, and therapeutic uses | REGENERON PHARMACEUTICALS, INC. (US) | 2020-02-25 | — | — | US | disclosed |
| EP-1755684-B1 | ALBUMIN-BINDING CONJUGATES COMPRISING A FATTY ACID AND PEG | UCB BIOPHARMA SPRL (BE) | 2016-08-31 | — | — | EP | disclosed |
| US-20160030591-A1 | BIOLOGICALLY ACTIVE MOLECULES, CONJUGATES THEREOF, AND THERAPEUTIC USES | REGENERON PHARMACEUTICALS, INC. | 2016-02-04 | — | — | US | disclosed |
| US-20160030591-A1 | BIOLOGICALLY ACTIVE MOLECULES, CONJUGATES THEREOF, AND THERAPEUTIC USES | REGENERON PHARMACEUTICALS, INC. | 2016-02-04 | — | — | US | disclosed |
| WO-2014145090-A1 | BIOLOGICALLY ACTIVE MOLECULES, CONJUGATES THEREOF, AND THERAPEUTIC USES | REGENERON PHARMACEUTICALS, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| US-7910618-B2 | Polyethylene glycol end-modified by an antibody or maleimide group on one end and a hydroxy fatty acid on the other; increased in vivo half life of insulin; antidiabetic agents | UCB PHARMA S.A. (BE) | 2011-03-22 | — | — | US | disclosed |
| US-7736635-B2 | Branched molecular scaffolds for linking polymer residues to biologically active moieties | UCB PHARMA S.A. (BE) | 2010-06-15 | — | — | US | disclosed |
| US-20080096957-A1 | Albumin-Binding Conjugates Comprising a Fatty Acid and Peg | CELLTECH R&D LIMITED (GB) | 2008-04-24 | — | — | US | disclosed |
| US-20080096957-A1 | Albumin-Binding Conjugates Comprising a Fatty Acid and Peg | CELLTECH R&D LIMITED (GB) | 2008-04-24 | — | — | US | disclosed |
| US-20080096957-A1 | Albumin-Binding Conjugates Comprising a Fatty Acid and Peg | CELLTECH R&D LIMITED (GB) | 2008-04-24 | — | — | US | disclosed |
| US-20070128150-A1 | Branched molecular scaffolds for linking polymer residues to biologically active moieties | UCB BIOPHARMA SPRL (BE) | 2007-06-07 | — | — | US | disclosed |
| EP-1755684-A2 | ALBUMIN-BINDING CONJUGATES COMPRISING A FATTY ACID AND PEG | Celltech R&D Limited (GB) | 2007-02-28 | — | — | EP | disclosed |
| EP-1699491-A2 | BRANCHED POLYETHYLENE GLYCOL FOR LINKING POLYMER RESIDUES TO ANTIBODIES | Celltech R&D Limited (GB) | 2006-09-13 | — | — | EP | disclosed |
| WO-2005117984-A2 | ALBUMIN-BINDING CONJUGATES COMPRISING A FATTY ACID AND PEG | CELLTECH R & D LIMITED (GB) | 2005-12-15 | — | — | WO | disclosed |
| WO-2005061005-A2 | BRANCHED POLYETHYLENE GLYCOL FOR LINKING POLYMER RESIDUES TO ANTIBODIES | CELLTECH R & D LIMITED (GB) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10570151-B2 | Biologically active molecules, conjugates thereof, and therapeutic uses | CD47, CD44, ACP1 | TDP1 1597/4885AKT1 954/4885DRD2 4612/4885 |
| US-20160030591-A1 | BIOLOGICALLY ACTIVE MOLECULES, CONJUGATES THEREOF, AND THERAPEUTIC USES | CD47, CD44, ACP1 | TDP1 1597/4885AKT1 954/4885DRD2 4612/4885 |
| US-11345715-B2 | Biologically active molecules, conjugates thereof, and therapeutic uses | CD47, CD44, ACP1 | TDP1 1597/4885AKT1 954/4885DRD2 4612/4885 |
| US-20070128150-A1 | Branched molecular scaffolds for linking polymer residues to biologically active moieties | ILK, ECPAS, FGB | TDP1 1600/4885AKT1 2421/4885DRD2 4171/4885 |
| US-20200277306-A1 | BIOLOGICALLY ACTIVE MOLECULES, CONJUGATES THEREOF, AND THERAPEUTIC USES | CD47, CD44, ACP1 | TDP1 1597/4885AKT1 954/4885DRD2 4612/4885 |
| US-20080096957-A1 | Albumin-Binding Conjugates Comprising a Fatty Acid and Peg | FABP1, FABP2, FABP4 | TDP1 4869/4885AKT1 4523/4885DRD2 4123/4885 |
| US-20260021192-A1 | PROTEINS HAVING A COVALENT WARHEAD | RIOX2, ORC3, DCLRE1A | TDP1 3545/4885AKT1 2046/4885DRD2 4539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.